Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-03-16 AGM Information
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Assemblea Ordinaria degli Azionisti 29 aprile 2022 – Relazioni Illustrative e proposte di delibera
AGM Information Classification · 99% confidence The document is titled "ASSEMBLEA DEGLI AZIONISTI DIASORIN S.p.A." (Shareholders' Meeting of Diasorin S.p.A.) and contains "RELAZIONI ILLUSTRATIVE E PROPOSTE DI DELIBERA SUGLI ARGOMENTI ALL'ORDINE DEL GIORNO" (Explanatory Reports and Proposals for Resolutions on the Agenda Items). The agenda items explicitly cover the approval of the 2021 Financial Statements (Point 1), the Remuneration Policy (Point 2), and the appointment of the Board of Directors (Point 3). These materials are prepared for a shareholders' meeting to vote on key corporate matters, which strongly indicates this is documentation related to the Annual General Meeting (AGM). The specific reference to proposals for deliberation and explanatory reports for the AGM agenda aligns perfectly with the AGM-R (AGM Information) definition, which covers presentations and materials shared during the AGM.
2022-03-16 Italian
DiaSorin S.p.A. – Ordinary Shareholders’ Meeting April 29, 2022 – Notice
AGM Information Classification · 99% confidence The document text is explicitly titled "Notice of Ordinary Shareholders' Meeting" and details the agenda for a meeting scheduled for April 29, 2022. The agenda includes items typical of an AGM, such as approval of Financial Statements, remuneration policy, appointment of the Board of Directors, and authorization for treasury share purchases. The metadata indicates this is an 'Informazione Regolamentata' (Regulated Information) from DiaSorin S.p.A. The content is a formal notice calling shareholders to vote on corporate matters, which aligns perfectly with the purpose of an Annual General Meeting (AGM) notice. Although it mentions financial statements (related to 10-K/IR), the primary function of this document is to convene the meeting and outline the voting items, making AGM-R the most appropriate classification. It is not a DEF 14A (Remuneration Report) or a DVA (Voting Results), but the notice *for* the meeting.
2022-03-16 English
DiaSorin S.p.A. - Assemblea Ordinaria degli Azionisti 29 aprile 2022 – Avviso di convocazione
AGM Information Classification · 99% confidence The document is an official notice titled "DiaSorin S.p.A. - Assemblea Ordinaria degli Azionisti 29 aprile 2022 – Avviso di convocazione" (Notice of Convocation for the Ordinary Shareholders' Meeting on April 29, 2022). It details the agenda (Ordine del Giorno), which includes the approval of the 2021 financial statements, remuneration policy, and the appointment of the Board of Directors and Statutory Auditors. The text explicitly discusses shareholder rights, voting procedures via a designated representative (Art. 135-undecies TUF), and the process for submitting questions before the meeting. This content is characteristic of materials related to an Annual General Meeting (AGM) or the formal notice preceding it. Since the document is the *convocation notice* itself, and the agenda covers standard AGM items, the most appropriate classification is AGM-R (AGM Information), as it directly pertains to the meeting logistics and agenda.
2022-03-16 Italian
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
Earnings Release Classification · 98% confidence The document is dated March 16, 2022, and its subject is 'DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021'. It contains detailed financial figures for FY 2021 (Revenues, EBITDA, Net Profit, Cash Flow) and provides FY 2022 guidance. It also mentions the approval of the Consolidated Financial Statements and the proposal for dividend distribution. The presence of detailed annual financial results, management commentary (though brief, it covers results and outlook), and the announcement of the approval of statutory financial statements strongly indicates this is an announcement related to the full-year financial performance. Since it is an initial announcement of results (not the full 10-K filing itself, which is typically much longer and filed with the SEC/CONSOB), it aligns best with an Earnings Release (ER) or potentially an Interim Report (IR) if it were mid-year, but for full-year results, ER is more appropriate for the initial press release format. However, the text also includes the approval of the Corporate Governance Report and the Remuneration Report details (though truncated), and the dividend announcement. Given the comprehensive nature of the financial summary and the date coinciding with the end of the fiscal year reporting cycle, it functions as the primary Earnings Release. The document explicitly states the Board examined and approved the Consolidated Financial Statements at December 31, 2021, which is the core function of an ER press release. FY 2021
2022-03-16 English
DiaSorin FY 2021 Results Presentation
Investor Presentation Classification · 95% confidence The document is titled "FY 2021 RESULTS" and contains detailed financial highlights for the fiscal year 2021, including Revenues, Adjusted EBITDA, Adjusted Net Result, and Free Cash Flow, presented in a tabular format. It also includes extensive sections on Business Development (mentioning the Luminex acquisition and convertible bond), Product Development, and Managerial outlook. This structure, focusing on comprehensive annual performance data, strongly indicates an Annual Report or a document closely associated with it, such as an Investor Presentation or Management Discussion & Analysis (MDA) that summarizes the full year. Given the depth of financial figures and the explicit reference to 'FY 2021 RESULTS' and the declaration by the manager responsible for accounting documents (Article 154-bis), it functions as the primary disclosure of annual results. While it has presentation elements (disclaimer, slides structure), the core content is the full-year financial summary. This aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed Investor Presentation (IP). Since it is a presentation summarizing the full year's results, Investor Presentation (IP) is a strong candidate, but the level of detail and the date (March 16, 2022, typically following the 10-K filing period) suggests it is the investor-facing summary of the annual performance, often released alongside or shortly after the 10-K. However, the content is highly focused on summarizing the full year's performance and outlook, which is the primary function of an Investor Presentation (IP) or a Management Discussion & Analysis (MDA) section of a 10-K. Given the format is a 'Presentation' with financial highlights and outlook, 'IP' (Investor Presentation) is the most fitting category for this specific document type, as it is not the formal 10-K filing itself, but the presentation material used to discuss those results.
2022-03-16 English
La crescita del business DiaSorin e l’acquisizione Luminex trainano l’aumento di ricavi, risultato netto e generazione di cassa nell’esercizio 2021
Earnings Release Classification · 95% confidence The document is a press release dated March 16, 2022, detailing the financial results for the fiscal year 2021 ("esercizio 2021"). It reports key figures like Revenues (€ 1,237.7 million), Adjusted EBITDA (€ 543.1 million), Net Income, and provides guidance for 2022. It also discusses strategic events like the Luminex acquisition and the presentation of the 2022-2025 industrial plan. This content structure—summarizing annual performance, providing key metrics, and offering forward guidance—is characteristic of an Earnings Release (ER) or a Management Discussion and Analysis (MDA). Since it focuses heavily on the summarized financial results and guidance immediately following the fiscal year end, it aligns best with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights). While it contains elements of MDA (management explanation), the primary focus is the headline financial performance announcement. The document length (57,976 chars) suggests it is comprehensive, moving beyond just the initial highlights, but the structure strongly suggests an official results announcement rather than a full Annual Report (10-K) or a comprehensive Interim Report (IR). Given the options, ER is the most fitting classification for a detailed annual results press release. FY 2021
2022-03-16 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.